US Venture Capital Opens Path to Funding for China Biotech Firms
(Bloomberg) — Faced with a moribund share sale outlook and emboldened by their growing recognition on the global stage, some Chinese biotechnology companies have found a new way to cash in on their innovative therapies. Most Read from Bloomberg They’re partnering with American venture capitalists to create new, US-based startups built around promising drug compounds,…